Keyphrases
Rhabdomyosarcoma
81%
Pediatric Soft Tissue Sarcomas
37%
Head-and-neck
26%
Event-free Survival
23%
Overall Survival
23%
Chemotherapy
22%
Children with Cancer
21%
Tumor
21%
Radiotherapy
20%
Ewing Sarcoma
17%
Childhood Cancer
14%
Pediatric Oncology
14%
Older Adults
13%
Confidence Interval
13%
Survivors
13%
Pediatric
12%
Amores
12%
Soft Tissue Sarcoma
11%
Childhood Cancer Patients
11%
Tumor Predisposition Syndrome
10%
Working Diagnosis
10%
Local Treatment
9%
Brachytherapy
9%
Netherlands
9%
Pediatric Patients
9%
Preadolescent children
9%
International Society
9%
Neuroblastoma
8%
EPS-SG
8%
Benign Mesenchymal Tumor
8%
Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
8%
Embryonal Rhabdomyosarcoma
8%
Metastatic Rhabdomyosarcoma
7%
High-dose Chemotherapy
7%
Health-related Quality of Life
7%
Pediatric Rhabdomyosarcoma
7%
Bevacizumab
6%
Nodal Involvement
6%
Quality of Life
6%
Psychosocial Intervention
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
5%
Cancer Predisposition Syndrome
5%
External Beam Radiotherapy
5%
Parameningeal
5%
Morphological Abnormalities
5%
Dutch
5%
Intervention Program
5%
Clinical Trials
5%
Alveolar Rhabdomyosarcoma
5%
Medicine and Dentistry
Rhabdomyosarcoma
100%
Pediatrics
55%
Neoplasm
50%
Soft Tissue Sarcoma
42%
Childhood Cancer
29%
Chemotherapy
28%
Neck
25%
Adolescence
24%
Radiation Therapy
22%
Overall Survival
21%
Disease
18%
Event Free Survival
17%
Ewing Sarcoma
17%
Malignant Neoplasm
15%
Local Therapy
11%
Lymph Node
10%
Brachytherapy
10%
Ganglioneuroblastoma
9%
Disease Predisposition
9%
Connective Tissue Cancer
7%
Prevalence
7%
Embryonal Rhabdomyosarcoma
7%
Diagnosis
7%
Metastatic Carcinoma
7%
Pediatrics Patient
6%
Solid Malignant Neoplasm
6%
External Beam Radiotherapy
6%
Morphology
5%
Clinical Trial
5%
Adverse Event
5%
Vincristine
5%
Oncology
5%
Dactinomycin
5%